Enabling The Outcome Through Enhancing Patient Accessibility

Cell and Gene Therapy (CGT) has emerged as one of the most transformative forces in modern medicine, reshaping healthcare and driving the future of next-generation treatments. Known by various names—cell and gene therapy, regenerative medicine, advanced therapies, or personalized medicine—the core promise remains the same: what was once a distant possibility is now a tangible reality. These therapies are offering new hope to patients battling diseases once considered incurable. However, despite significant scientific advancements, a critical challenge persists: ensuring that these therapies are accessible to the patients who need them most.

This issue was the central theme of Aruna Mor's keynote at the Advanced Therapies Congress in London. As Chief Commercial Officer at Cryoport Systems with over 20 years of experience in the CGT field, Aruna shared invaluable insights into both the progress made and the barriers that remain to widespread access. Her address underscored the urgent need for a more equitable approach to delivering these life-changing therapies to all patients who stand to benefit.